{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:40:25Z","timestamp":1793727625119,"version":"4.6.1"},"reference-count":165,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":74,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100012620","name":"Taishan Scholar Foundation of Shandong Province","doi-asserted-by":"publisher","award":["tsqn202507348"],"award-info":[{"award-number":["tsqn202507348"]}],"id":[{"id":"10.13039\/100012620","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2024M762334"],"award-info":[{"award-number":["2024M762334"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2024MH242"],"award-info":[{"award-number":["ZR2024MH242"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373005"],"award-info":[{"award-number":["82373005"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Commun Signal"],"DOI":"10.1186\/s12964-026-03017-5","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T08:16:02Z","timestamp":1781856962000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Alternative splicing rewires breast cancer and opens therapeutic avenues"],"prefix":"10.1186","volume":"24","author":[{"given":"Yuhan","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiran","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahsa Maghsoudy","family":"Kasvaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0576-8513","authenticated-orcid":false,"given":"Qifeng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,19]]},"reference":[{"issue":"1","key":"3017_CR1","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, et al. Cancer statistics, 2025. CA Cancer J Clin. 2025;75(1):10\u201345.","journal-title":"CA Cancer J Clin"},{"key":"3017_CR2","doi-asserted-by":"publisher","first-page":"102108","DOI":"10.1016\/j.ctrv.2020.102108","volume":"91","author":"H Zhang","year":"2020","unstructured":"Zhang H, et al. Special subtypes with favorable prognosis in breast cancer: A registry-based cohort study and network meta-analysis. Cancer Treat Rev. 2020;91:102108.","journal-title":"Cancer Treat Rev"},{"key":"3017_CR3","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.semcancer.2019.08.012","volume":"60","author":"Y Liang","year":"2020","unstructured":"Liang Y, et al. Metastatic heterogeneity of breast cancer: Molecular mechanism and potential therapeutic targets. Semin Cancer Biol. 2020;60:14\u201327.","journal-title":"Semin Cancer Biol"},{"issue":"6","key":"3017_CR4","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1016\/j.cell.2013.02.014","volume":"152","author":"TI Lee","year":"2013","unstructured":"Lee TI, Young RA. Transcriptional regulation and its misregulation in disease. Cell. 2013;152(6):1237\u201351.","journal-title":"Cell"},{"issue":"4","key":"3017_CR5","doi-asserted-by":"publisher","first-page":"e1707","DOI":"10.1002\/wrna.1707","volume":"13","author":"M Reixachs-Sole","year":"2022","unstructured":"Reixachs-Sole M, Eyras E. Uncovering the impacts of alternative splicing on the proteome with current omics techniques. Wiley Interdiscip Rev RNA. 2022;13(4):e1707.","journal-title":"Wiley Interdiscip Rev RNA"},{"key":"3017_CR6","doi-asserted-by":"publisher","first-page":"100728","DOI":"10.1016\/j.drup.2020.100728","volume":"53","author":"R Sciarrillo","year":"2020","unstructured":"Sciarrillo R, et al. The role of alternative splicing in cancer: From oncogenesis to drug resistance. Drug Resist Updat. 2020;53:100728.","journal-title":"Drug Resist Updat"},{"issue":"9","key":"3017_CR7","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.tig.2023.04.008","volume":"39","author":"H Shenasa","year":"2023","unstructured":"Shenasa H, Bentley DL. Pre-mRNA splicing and its cotranscriptional connections. Trends Genet. 2023;39(9):672\u201385.","journal-title":"Trends Genet"},{"issue":"1","key":"3017_CR8","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1002\/wrna.1140","volume":"4","author":"L De Conti","year":"2013","unstructured":"De Conti L, Baralle M, Buratti E. Exon and intron definition in pre-mRNA splicing. Wiley Interdiscip Rev RNA. 2013;4(1):49\u201360.","journal-title":"Wiley Interdiscip Rev RNA"},{"issue":"1","key":"3017_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/wrna.1815","volume":"15","author":"N Wang","year":"2024","unstructured":"Wang N, Hu Y, Wang Z. Regulation of alternative splicing: Functional interplay with epigenetic modifications and its implication to cancer. Wiley Interdiscip Rev RNA. 2023;15(1):e1815.","journal-title":"Wiley Interdiscip Rev RNA"},{"issue":"8","key":"3017_CR10","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1007\/s00439-016-1683-5","volume":"135","author":"T Geuens","year":"2016","unstructured":"Geuens T, Bouhy D, Timmerman V. The hnRNP family: insights into their role in health and disease. Hum Genet. 2016;135(8):851\u201367.","journal-title":"Hum Genet"},{"issue":"19","key":"3017_CR11","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1038\/onc.2015.318","volume":"35","author":"A Sveen","year":"2016","unstructured":"Sveen A, et al. Aberrant RNA splicing in cancer; expression changes and driver mutations of splicing factor genes. Oncogene. 2016;35(19):2413\u201327.","journal-title":"Oncogene"},{"issue":"5968","key":"3017_CR12","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1126\/science.1184208","volume":"327","author":"RF Luco","year":"2010","unstructured":"Luco RF, et al. Regulation of alternative splicing by histone modifications. Science. 2010;327(5968):996\u20131000.","journal-title":"Science"},{"issue":"4","key":"3017_CR13","doi-asserted-by":"publisher","first-page":"115450","DOI":"10.1016\/j.celrep.2025.115450","volume":"44","author":"L Choppavarapu","year":"2025","unstructured":"Choppavarapu L, et al. Hi-C profiling in tissues reveals 3D chromatin-regulated breast tumor heterogeneity informing a looping-mediated therapeutic avenue. Cell Rep. 2025;44(4):115450.","journal-title":"Cell Rep"},{"issue":"11","key":"3017_CR14","doi-asserted-by":"publisher","first-page":"194631","DOI":"10.1016\/j.bbagrm.2020.194631","volume":"1863","author":"Y Yang","year":"2020","unstructured":"Yang Y, et al. The 3D genomic landscape of differential response to EGFR\/HER2 inhibition in endocrine-resistant breast cancer cells. Biochim Biophys Acta Gene Regul Mech. 2020;1863(11):194631.","journal-title":"Biochim Biophys Acta Gene Regul Mech"},{"issue":"12","key":"3017_CR15","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1038\/s41388-023-02602-z","volume":"42","author":"C Achour","year":"2023","unstructured":"Achour C, et al. METTL3 regulates breast cancer-associated alternative splicing switches. Oncogene. 2023;42(12):911\u201325.","journal-title":"Oncogene"},{"issue":"6543","key":"3017_CR16","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc7531","volume":"372","author":"L Fish","year":"2021","unstructured":"Fish L, et al. A prometastatic splicing program regulated by SNRPA1 interactions with structured RNA elements. Science. 2021;372(6543):eabc7531.","journal-title":"Science"},{"issue":"10","key":"3017_CR17","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/nrg3778","volume":"15","author":"XD Fu","year":"2014","unstructured":"Fu XD, Ares M Jr. Context-dependent control of alternative splicing by RNA-binding proteins. Nat Rev Genet. 2014;15(10):689\u2013701.","journal-title":"Nat Rev Genet"},{"issue":"26","key":"3017_CR18","doi-asserted-by":"publisher","first-page":"E3374","DOI":"10.1073\/pnas.1418603112","volume":"112","author":"KK Nakka","year":"2015","unstructured":"Nakka KK, et al. Nuclear matrix-associated protein SMAR1 regulates alternative splicing via HDAC6-mediated deacetylation of Sam68. Proc Natl Acad Sci. 2015;112(26):E3374\u201383.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"3017_CR19","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s13046-021-01978-8","volume":"40","author":"JX Du","year":"2021","unstructured":"Du JX, et al. Splicing factor SRSF1 promotes breast cancer progression via oncogenic splice switching of PTPMT1. J Exp Clin Cancer Res. 2021;40(1):171.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"3017_CR20","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.celrep.2012.11.020","volume":"3","author":"V Ben-Hur","year":"2013","unstructured":"Ben-Hur V, et al. S6K1 alternative splicing modulates its oncogenic activity and regulates mTORC1. Cell Rep. 2013;3(1):103\u201315.","journal-title":"Cell Rep"},{"issue":"4","key":"3017_CR21","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1002\/1878-0261.12444","volume":"13","author":"EA Teslow","year":"2019","unstructured":"Teslow EA, et al. Obesity-induced MBD2_v2 expression promotes tumor-initiating triple-negative breast cancer stem cells. Mol Oncol. 2019;13(4):894\u2013908.","journal-title":"Mol Oncol"},{"issue":"5","key":"3017_CR22","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1158\/0008-5472.CAN-20-2876","volume":"81","author":"Z Liu","year":"2021","unstructured":"Liu Z, et al. Hypoxia-Induced Suppression of Alternative Splicing of MBD2 Promotes Breast Cancer Metastasis via Activation of FZD1. Cancer Res. 2021;81(5):1265\u201378.","journal-title":"Cancer Res"},{"issue":"10","key":"3017_CR23","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1080\/15476286.2015.1076610","volume":"12","author":"H Gautrey","year":"2015","unstructured":"Gautrey H, et al. SRSF3 and hnRNP H1 regulate a splicing hotspot of HER2 in breast cancer cells. RNA Biol. 2015;12(10):1139\u201351.","journal-title":"RNA Biol"},{"issue":"15","key":"3017_CR24","doi-asserted-by":"publisher","first-page":"E3426","DOI":"10.1073\/pnas.1714573115","volume":"115","author":"H Ke","year":"2018","unstructured":"Ke H, et al. Loss of TDP43 inhibits progression of triple-negative breast cancer in coordination with SRSF3. Proc Natl Acad Sci USA. 2018;115(15):E3426\u201335.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"12","key":"3017_CR25","doi-asserted-by":"publisher","first-page":"e51497","DOI":"10.1371\/journal.pone.0051497","volume":"7","author":"HL Gautrey","year":"2012","unstructured":"Gautrey HL, Tyson-Capper AJ. Regulation of Mcl-1 by SRSF1 and SRSF5 in cancer cells. PLoS ONE. 2012;7(12):e51497.","journal-title":"PLoS ONE"},{"issue":"24","key":"3017_CR26","doi-asserted-by":"publisher","first-page":"22641","DOI":"10.1074\/jbc.M501070200","volume":"280","author":"D Garneau","year":"2005","unstructured":"Garneau D, et al. Heterogeneous nuclear ribonucleoprotein F\/H proteins modulate the alternative splicing of the apoptotic mediator Bcl-x. J Biol Chem. 2005;280(24):22641\u201350.","journal-title":"J Biol Chem"},{"issue":"19","key":"3017_CR27","doi-asserted-by":"publisher","first-page":"4084","DOI":"10.1038\/emboj.2011.259","volume":"30","author":"CV Lefave","year":"2011","unstructured":"Lefave CV, et al. Splicing factor hnRNPH drives an oncogenic splicing switch in gliomas. EMBO J. 2011;30(19):4084\u201397.","journal-title":"EMBO J"},{"issue":"3","key":"3017_CR28","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.3892\/or.2015.4110","volume":"34","author":"TJ Loh","year":"2015","unstructured":"Loh TJ, et al. CD44 alternative splicing and hnRNP A1 expression are associated with the metastasis of breast cancer. Oncol Rep. 2015;34(3):1231\u20138.","journal-title":"Oncol Rep"},{"issue":"2","key":"3017_CR29","doi-asserted-by":"publisher","first-page":"e1612","DOI":"10.1002\/wrna.1612","volume":"12","author":"Y Liu","year":"2021","unstructured":"Liu Y, Shi SL. The roles of hnRNP A2\/B1 in RNA biology and disease. Wiley Interdiscip Rev RNA. 2021;12(2):e1612.","journal-title":"Wiley Interdiscip Rev RNA"},{"issue":"6","key":"3017_CR30","doi-asserted-by":"publisher","first-page":"e2262","DOI":"10.1038\/cddis.2016.168","volume":"7","author":"R Singh","year":"2016","unstructured":"Singh R, et al. Regulation of alternative splicing of Bcl-x by BC200 contributes to breast cancer pathogenesis. Cell Death Dis. 2016;7(6):e2262.","journal-title":"Cell Death Dis"},{"issue":"11","key":"3017_CR31","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1101\/gad.241968.114","volume":"28","author":"Y Xu","year":"2014","unstructured":"Xu Y, et al. Cell type-restricted activity of hnRNPM promotes breast cancer metastasis via regulating alternative splicing. Genes Dev. 2014;28(11):1191\u2013203.","journal-title":"Genes Dev"},{"issue":"9","key":"3017_CR32","doi-asserted-by":"publisher","first-page":"654","DOI":"10.2174\/1568009620666200621153831","volume":"20","author":"Y Vadlamudi","year":"2020","unstructured":"Vadlamudi Y, Dey DK, Kang SC. Emerging Multi-cancer Regulatory Role of ESRP1: Orchestration of Alternative Splicing to Control EMT. Curr Cancer Drug Targets. 2020;20(9):654\u201365.","journal-title":"Curr Cancer Drug Targets"},{"issue":"12","key":"3017_CR33","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1080\/15476286.2018.1551692","volume":"15","author":"A Tyson-Capper","year":"2018","unstructured":"Tyson-Capper A, Gautrey H. Regulation of Mcl-1 alternative splicing by hnRNP F, H1 and K in breast cancer cells. RNA Biol. 2018;15(12):1448\u201357.","journal-title":"RNA Biol"},{"issue":"10","key":"3017_CR34","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1261\/rna.066712.118","volume":"24","author":"SE Harvey","year":"2018","unstructured":"Harvey SE, et al. Coregulation of alternative splicing by hnRNPM and ESRP1 during EMT. RNA. 2018;24(10):1326\u201338.","journal-title":"RNA"},{"issue":"4","key":"3017_CR35","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1002\/path.4483","volume":"235","author":"SL Maguire","year":"2015","unstructured":"Maguire SL, et al. SF3B1 mutations constitute a novel therapeutic target in breast cancer. J Pathol. 2015;235(4):571\u201380.","journal-title":"J Pathol"},{"issue":"8","key":"3017_CR36","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1038\/onc.2016.279","volume":"36","author":"AK Kesarwani","year":"2017","unstructured":"Kesarwani AK, et al. Cancer-associated SF3B1 mutants recognize otherwise inaccessible cryptic 3\u2019 splice sites within RNA secondary structures. Oncogene. 2017;36(8):1123\u201333.","journal-title":"Oncogene"},{"key":"3017_CR37","doi-asserted-by":"crossref","unstructured":"Liu B, et al. Mutant SF3B1 promotes AKT- and NF-kappaB-driven mammary tumorigenesis. J Clin Invest. 2021;131(1):e138315.","DOI":"10.1172\/JCI138315"},{"issue":"5","key":"3017_CR38","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.ccell.2015.04.006","volume":"27","author":"E Kim","year":"2015","unstructured":"Kim E, et al. SRSF2 Mutations Contribute to Myelodysplasia by Mutant-Specific Effects on Exon Recognition. Cancer Cell. 2015;27(5):617\u201330.","journal-title":"Cancer Cell"},{"issue":"5","key":"3017_CR39","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.ccell.2015.04.008","volume":"27","author":"CL Shirai","year":"2015","unstructured":"Shirai CL, et al. Mutant U2AF1 Expression Alters Hematopoiesis and Pre-mRNA Splicing In Vivo. Cancer Cell. 2015;27(5):631\u201343.","journal-title":"Cancer Cell"},{"key":"3017_CR40","doi-asserted-by":"publisher","first-page":"6042","DOI":"10.1038\/ncomms7042","volume":"6","author":"V Madan","year":"2015","unstructured":"Madan V, et al. Aberrant splicing of U12-type introns is the hallmark of ZRSR2 mutant myelodysplastic syndrome. Nat Commun. 2015;6:6042.","journal-title":"Nat Commun"},{"issue":"5","key":"3017_CR41","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.molcel.2013.11.010","volume":"52","author":"EG Bechara","year":"2013","unstructured":"Bechara EG, et al. RBM5, 6, and 10 differentially regulate NUMB alternative splicing to control cancer cell proliferation. Mol Cell. 2013;52(5):720\u201333.","journal-title":"Mol Cell"},{"issue":"3","key":"3017_CR42","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1007\/s12282-020-01045-8","volume":"27","author":"L Zhang","year":"2020","unstructured":"Zhang L, et al. Knockdown of SF3B1 inhibits cell proliferation, invasion and migration triggering apoptosis in breast cancer via aberrant splicing. Breast Cancer. 2020;27(3):464\u201376.","journal-title":"Breast Cancer"},{"issue":"13","key":"3017_CR43","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.7150\/ijbs.46751","volume":"16","author":"X Zheng","year":"2020","unstructured":"Zheng X, et al. Serine\/arginine-rich splicing factors: the bridge linking alternative splicing and cancer. Int J Biol Sci. 2020;16(13):2442\u201353.","journal-title":"Int J Biol Sci"},{"issue":"1","key":"3017_CR44","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.molcel.2015.09.005","volume":"60","author":"O Anczukow","year":"2015","unstructured":"Anczukow O, et al. SRSF1-Regulated Alternative Splicing in Breast Cancer. Mol Cell. 2015;60(1):105\u201317.","journal-title":"Mol Cell"},{"issue":"3","key":"3017_CR45","doi-asserted-by":"publisher","first-page":"807","DOI":"10.7150\/ijbs.55120","volume":"17","author":"W Xie","year":"2021","unstructured":"Xie W, et al. Crucial roles of different RNA-binding hnRNP proteins in Stem Cells. Int J Biol Sci. 2021;17(3):807\u201317.","journal-title":"Int J Biol Sci"},{"key":"3017_CR46","doi-asserted-by":"crossref","unstructured":"Li WJ et al. Profiling PRMT methylome reveals roles of hnRNPA1 arginine methylation in RNA splicing and cell growth. Nat Commun. 2021;12(1):1946.","DOI":"10.1038\/s41467-021-21963-1"},{"issue":"18","key":"3017_CR47","doi-asserted-by":"publisher","first-page":"3225","DOI":"10.1128\/MCB.00426-15","volume":"35","author":"J Yang","year":"2015","unstructured":"Yang J, et al. LIN28A Modulates Splicing and Gene Expression Programs in Breast Cancer Cells. Mol Cell Biol. 2015;35(18):3225\u201343.","journal-title":"Mol Cell Biol"},{"issue":"10","key":"3017_CR48","doi-asserted-by":"publisher","first-page":"e1460","DOI":"10.1002\/ctm2.1460","volume":"13","author":"ZM Zhu","year":"2023","unstructured":"Zhu ZM, et al. Crosstalk between m6A modification and alternative splicing during cancer progression. Clin Transl Med. 2023;13(10):e1460.","journal-title":"Clin Transl Med"},{"key":"3017_CR49","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.canlet.2021.07.015","volume":"518","author":"BJ Petri","year":"2021","unstructured":"Petri BJ, et al. HNRNPA2B1 regulates tamoxifen- and fulvestrant-sensitivity and hallmarks of endocrine resistance in breast cancer cells. Cancer Lett. 2021;518:152\u201368.","journal-title":"Cancer Lett"},{"key":"3017_CR50","doi-asserted-by":"crossref","unstructured":"Gokmen-Polar Y, et al. Splicing factor ESRP1 controls ER-positive breast cancer by altering metabolic pathways. EMBO Rep. 2019;20(2):e46078.","DOI":"10.15252\/embr.201846078"},{"issue":"10","key":"3017_CR51","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1038\/nrc2222","volume":"7","author":"JA Menendez","year":"2007","unstructured":"Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer. 2007;7(10):763\u201377.","journal-title":"Nat Rev Cancer"},{"issue":"36","key":"3017_CR52","doi-asserted-by":"publisher","first-page":"24364","DOI":"10.18632\/oncotarget.25273","volume":"9","author":"C Angelucci","year":"2018","unstructured":"Angelucci C, et al. Pivotal role of human stearoyl-CoA desaturases (SCD1 and 5) in breast cancer progression: oleic acid-based effect of SCD1 on cell migration and a novel pro-cell survival role for SCD5. Oncotarget. 2018;9(36):24364\u201380.","journal-title":"Oncotarget"},{"issue":"15","key":"3017_CR53","doi-asserted-by":"publisher","first-page":"4430","DOI":"10.1158\/0008-5472.CAN-16-0530","volume":"76","author":"D Samanta","year":"2016","unstructured":"Samanta D, et al. PHGDH Expression Is Required for Mitochondrial Redox Homeostasis, Breast Cancer Stem Cell Maintenance, and Lung Metastasis. Cancer Res. 2016;76(15):4430\u201342.","journal-title":"Cancer Res"},{"issue":"7360","key":"3017_CR54","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nature10350","volume":"476","author":"R Possemato","year":"2011","unstructured":"Possemato R, et al. Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature. 2011;476(7360):346\u201350.","journal-title":"Nature"},{"issue":"1","key":"3017_CR55","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s12943-018-0914-x","volume":"17","author":"K Zeng","year":"2018","unstructured":"Zeng K, et al. The pro-metastasis effect of circANKS1B in breast cancer. Mol Cancer. 2018;17(1):160.","journal-title":"Mol Cancer"},{"issue":"43","key":"3017_CR56","doi-asserted-by":"publisher","first-page":"11440","DOI":"10.1073\/pnas.1708447114","volume":"114","author":"S Singh","year":"2017","unstructured":"Singh S, et al. Intragenic DNA methylation and BORIS-mediated cancer-specific splicing contribute to the Warburg effect. Proc Natl Acad Sci U S A. 2017;114(43):11440\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"3017_CR57","doi-asserted-by":"publisher","first-page":"107416","DOI":"10.1016\/j.jbc.2024.107416","volume":"300","author":"A Pandey","year":"2024","unstructured":"Pandey A, Kakani P, Shukla S. CTCF and BORIS-mediated autophagy regulation via alternative splicing of BNIP3L in breast cancer. J Biol Chem. 2024;300(7):107416.","journal-title":"J Biol Chem"},{"issue":"2","key":"3017_CR58","doi-asserted-by":"publisher","first-page":"115267","DOI":"10.1016\/j.celrep.2025.115267","volume":"44","author":"P Kakani","year":"2025","unstructured":"Kakani P, et al. Hypoxia-induced CTCF mediates alternative splicing via coupling chromatin looping and RNA Pol II pause to promote EMT in breast cancer. Cell Rep. 2025;44(2):115267.","journal-title":"Cell Rep"},{"issue":"1","key":"3017_CR59","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.tig.2022.10.004","volume":"39","author":"I Orsolic","year":"2023","unstructured":"Orsolic I, Carrier A, Esteller M. Genetic and epigenetic defects of the RNA modification machinery in cancer. Trends Genet. 2023;39(1):74\u201388.","journal-title":"Trends Genet"},{"issue":"1","key":"3017_CR60","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/s12943-019-1109-9","volume":"18","author":"L He","year":"2019","unstructured":"He L, et al. Functions of N6-methyladenosine and its role in cancer. Mol Cancer. 2019;18(1):176.","journal-title":"Mol Cancer"},{"issue":"1","key":"3017_CR61","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13046-025-03279-w","volume":"44","author":"X Lv","year":"2025","unstructured":"Lv X, et al. Targeting RNA splicing modulation: new perspectives for anticancer strategy? J Exp Clin Cancer Res. 2025;44(1):32.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"3017_CR62","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/nrc3409","volume":"13","author":"Y Yang","year":"2013","unstructured":"Yang Y, Bedford MT. Protein arginine methyltransferases and cancer. Nat Rev Cancer. 2013;13(1):37\u201350.","journal-title":"Nat Rev Cancer"},{"issue":"24","key":"3017_CR63","doi-asserted-by":"publisher","first-page":"4597","DOI":"10.4161\/cc.22871","volume":"11","author":"RM Baldwin","year":"2012","unstructured":"Baldwin RM, et al. Alternatively spliced protein arginine methyltransferase 1 isoform PRMT1v2 promotes the survival and invasiveness of breast cancer cells. Cell Cycle. 2012;11(24):4597\u2013612.","journal-title":"Cell Cycle"},{"key":"3017_CR64","doi-asserted-by":"crossref","unstructured":"Martinez S, et al. Role of PRMT1 and PRMT5 in Breast Cancer. Int J Mol Sci. 2024;25(16):8854.","DOI":"10.3390\/ijms25168854"},{"issue":"1","key":"3017_CR65","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1186\/s12885-023-11260-z","volume":"23","author":"S O\u2019Brien","year":"2023","unstructured":"O\u2019Brien S, et al. Inhibiting PRMT5 induces DNA damage and increases anti-proliferative activity of Niraparib, a PARP inhibitor, in models of breast and ovarian cancer. BMC Cancer. 2023;23(1):775.","journal-title":"BMC Cancer"},{"issue":"6","key":"3017_CR66","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1101\/gad.455708","volume":"22","author":"M Beltran","year":"2008","unstructured":"Beltran M, et al. A natural antisense transcript regulates Zeb2\/Sip1 gene expression during Snail1-induced epithelial-mesenchymal transition. Genes Dev. 2008;22(6):756\u201369.","journal-title":"Genes Dev"},{"issue":"4","key":"3017_CR67","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.cell.2018.12.021","volume":"176","author":"JN Vo","year":"2019","unstructured":"Vo JN, et al. The Landscape of Circular RNA in Cancer. Cell. 2019;176(4):869\u2013e88113.","journal-title":"Cell"},{"issue":"1","key":"3017_CR68","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1111\/jcmm.14737","volume":"24","author":"H Zhou","year":"2020","unstructured":"Zhou H, et al. circFBXL5 promotes breast cancer progression by sponging miR-660. J Cell Mol Med. 2020;24(1):356\u201361.","journal-title":"J Cell Mol Med"},{"issue":"1","key":"3017_CR69","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/s41420-022-00965-y","volume":"8","author":"Y Yu","year":"2022","unstructured":"Yu Y, Fang L. CircRPAP2 regulates the alternative splicing of PTK2 by binding to SRSF1 in breast cancer. Cell Death Discov. 2022;8(1):152.","journal-title":"Cell Death Discov"},{"issue":"9","key":"3017_CR70","doi-asserted-by":"publisher","first-page":"2754","DOI":"10.1016\/j.ymthe.2021.08.002","volume":"29","author":"J Ma","year":"2021","unstructured":"Ma J, et al. An antisense circular RNA circSCRIB enhances cancer progression by suppressing parental gene splicing and translation. Mol Ther. 2021;29(9):2754\u201368.","journal-title":"Mol Ther"},{"issue":"6","key":"3017_CR71","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12061453","volume":"12","author":"J Elhasnaoui","year":"2020","unstructured":"Elhasnaoui J, et al. DSCAM-AS1-Driven Proliferation of Breast Cancer Cells Involves Regulation of Alternative Exon Splicing and 3\u2019-End Usage. Cancers (Basel). 2020;12(6):1453.","journal-title":"Cancers (Basel)"},{"issue":"2","key":"3017_CR72","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3233\/BD-201010","volume":"40","author":"M Tarighi","year":"2021","unstructured":"Tarighi M, et al. Long non-coding RNA (lncRNA) DSCAM-AS1 is upregulated in breast cancer. Breast Dis. 2021;40(2):63\u20138.","journal-title":"Breast Dis"},{"key":"3017_CR73","doi-asserted-by":"publisher","first-page":"12791","DOI":"10.1038\/ncomms12791","volume":"7","author":"YS Niknafs","year":"2016","unstructured":"Niknafs YS, et al. The lncRNA landscape of breast cancer reveals a role for DSCAM-AS1 in breast cancer progression. Nat Commun. 2016;7:12791.","journal-title":"Nat Commun"},{"issue":"1","key":"3017_CR74","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1101\/gad.270959.115","volume":"30","author":"G Arun","year":"2016","unstructured":"Arun G, et al. Differentiation of mammary tumors and reduction in metastasis upon Malat1 lncRNA loss. Genes Dev. 2016;30(1):34\u201351.","journal-title":"Genes Dev"},{"issue":"8","key":"3017_CR75","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.15252\/embr.201643370","volume":"18","author":"M Pruszko","year":"2017","unstructured":"Pruszko M, et al. The mutant p53-ID4 complex controls VEGFA isoforms by recruiting lncRNA MALAT1. EMBO Rep. 2017;18(8):1331\u201351.","journal-title":"EMBO Rep"},{"key":"3017_CR76","doi-asserted-by":"crossref","unstructured":"Song YJ, et al. LncRNA-splicing factor condensates regulate hypoxia-responsive pre-mRNA processing near nuclear speckles. Mol Cell. 2026;86(6):1061\u20131080.e10.","DOI":"10.1016\/j.molcel.2026.02.014"},{"issue":"1","key":"3017_CR77","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1080\/15476286.2022.2062846","volume":"19","author":"X Wang","year":"2022","unstructured":"Wang X, et al. Mechanisms of non-coding RNA-modulated alternative splicing in cancer. RNA Biol. 2022;19(1):541\u20137.","journal-title":"RNA Biol"},{"issue":"3","key":"3017_CR78","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/s41568-022-00541-7","volume":"23","author":"RK Bradley","year":"2023","unstructured":"Bradley RK, Anczuk\u00f3w O. RNA splicing dysregulation and the hallmarks of cancer. Nat Rev Cancer. 2023;23(3):135\u201355.","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"3017_CR79","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1038\/s41419-021-03661-4","volume":"12","author":"F Chen","year":"2021","unstructured":"Chen F, et al. MCPIP1-mediated NFIC alternative splicing inhibits proliferation of triple-negative breast cancer via cyclin D1-Rb-E2F1 axis. Cell Death Dis. 2021;12(4):370.","journal-title":"Cell Death Dis"},{"issue":"4","key":"3017_CR80","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.bbrc.2012.05.070","volume":"422","author":"D Pan","year":"2012","unstructured":"Pan D, et al. IL-7 splicing variant IL-7delta5 induces human breast cancer cell proliferation via activation of PI3K\/Akt pathway. Biochem Biophys Res Commun. 2012;422(4):727\u201331.","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"3017_CR81","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.3892\/or.2017.5786","volume":"38","author":"J Zhong","year":"2017","unstructured":"Zhong J, et al. PRMT2beta, a C-terminal splice variant of PRMT2, inhibits the growth of breast cancer cells. Oncol Rep. 2017;38(2):1303\u201311.","journal-title":"Oncol Rep"},{"key":"3017_CR82","doi-asserted-by":"publisher","first-page":"1190479","DOI":"10.3389\/fendo.2023.1190479","volume":"14","author":"S Ha","year":"2023","unstructured":"Ha S, Gujrati H, Wang BD. Aberrant PI3Kdelta splice isoform as a potential biomarker and novel therapeutic target for endocrine cancers. Front Endocrinol (Lausanne). 2023;14:1190479.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"3017_CR83","doi-asserted-by":"crossref","unstructured":"Han B-y, et al. HNRNPU promotes the progression of triple-negative breast cancer via RNA transcription and alternative splicing mechanisms. Cell Death Dis. 2022;13(11):940.","DOI":"10.1038\/s41419-022-05376-6"},{"issue":"12","key":"3017_CR84","doi-asserted-by":"publisher","first-page":"3915","DOI":"10.1111\/cas.16356","volume":"115","author":"S Yu","year":"2024","unstructured":"Yu S, et al. SNRPB2 promotes triple-negative breast cancer progression by controlling alternative splicing of MDM4 pre-mRNA. Cancer Sci. 2024;115(12):3915\u201327.","journal-title":"Cancer Sci"},{"key":"3017_CR85","doi-asserted-by":"crossref","unstructured":"Gu J, et al. Prognosis assessment of CD44(+)\/CD24(-) in breast cancer patients: a systematic review and meta-analysis. Arch Gynecol Obstet. 2022;306(4):1147\u201360.","DOI":"10.1007\/s00404-022-06402-w"},{"issue":"3\u20134","key":"3017_CR86","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1101\/gad.319889.118","volume":"33","author":"H Zhang","year":"2019","unstructured":"Zhang H, et al. CD44 splice isoform switching determines breast cancer stem cell state. Genes Dev. 2019;33(3\u20134):166\u201379.","journal-title":"Genes Dev"},{"issue":"1","key":"3017_CR87","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/nrm1004","volume":"4","author":"H Ponta","year":"2003","unstructured":"Ponta H, Sherman L, Herrlich PA. CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol. 2003;4(1):33\u201345.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"11","key":"3017_CR88","doi-asserted-by":"publisher","first-page":"2566","DOI":"10.1002\/ijc.29642","volume":"137","author":"BT Preca","year":"2015","unstructured":"Preca BT, et al. A self-enforcing CD44s\/ZEB1 feedback loop maintains EMT and stemness properties in cancer cells. Int J Cancer. 2015;137(11):2566\u201377.","journal-title":"Int J Cancer"},{"issue":"3","key":"3017_CR89","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.celrep.2014.03.059","volume":"7","author":"HL Goel","year":"2014","unstructured":"Goel HL, et al. Regulated splicing of the alpha6 integrin cytoplasmic domain determines the fate of breast cancer stem cells. Cell Rep. 2014;7(3):747\u201361.","journal-title":"Cell Rep"},{"issue":"11","key":"3017_CR90","doi-asserted-by":"publisher","first-page":"100821","DOI":"10.1016\/j.xcrm.2022.100821","volume":"3","author":"R Uceda-Castro","year":"2022","unstructured":"Uceda-Castro R, et al. Re-purposing the pro-senescence properties of doxorubicin to introduce immunotherapy in breast cancer brain metastasis. Cell Rep Med. 2022;3(11):100821.","journal-title":"Cell Rep Med"},{"issue":"2","key":"3017_CR91","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s13402-022-00665-w","volume":"45","author":"H Al Kawas","year":"2022","unstructured":"Al Kawas H, et al. How VEGF-A and its splice variants affect breast cancer development - clinical implications. Cell Oncol (Dordr). 2022;45(2):227\u201339.","journal-title":"Cell Oncol (Dordr)"},{"issue":"20","key":"3017_CR92","doi-asserted-by":"publisher","first-page":"5780","DOI":"10.1158\/0008-5472.CAN-17-1394","volume":"78","author":"FL Zhang","year":"2018","unstructured":"Zhang FL, et al. Cancer-Associated MORC2-Mutant M276I Regulates an hnRNPM-Mediated CD44 Splicing Switch to Promote Invasion and Metastasis in Triple-Negative Breast Cancer. Cancer Res. 2018;78(20):5780\u201392.","journal-title":"Cancer Res"},{"key":"3017_CR93","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1038\/ncomms1892","volume":"3","author":"T Yae","year":"2012","unstructured":"Yae T, et al. Alternative splicing of CD44 mRNA by ESRP1 enhances lung colonization of metastatic cancer cell. Nat Commun. 2012;3:883.","journal-title":"Nat Commun"},{"issue":"5","key":"3017_CR94","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1016\/j.cell.2014.07.013","volume":"158","author":"N Aceto","year":"2014","unstructured":"Aceto N, et al. Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell. 2014;158(5):1110\u201322.","journal-title":"Cell"},{"key":"3017_CR95","doi-asserted-by":"crossref","unstructured":"Zinn R, et al. RAC1B: A Guardian of the Epithelial Phenotype and Protector Against Epithelial-Mesenchymal Transition. Cells. 2019;8(12):1569.","DOI":"10.3390\/cells8121569"},{"key":"3017_CR96","doi-asserted-by":"crossref","unstructured":"Eiden C, Ungefroren H. The Ratio of RAC1B to RAC1 Expression in Breast Cancer Cell Lines as a Determinant of Epithelial\/Mesenchymal Differentiation and Migratory Potential. Cells. 2021;10(2):351.","DOI":"10.3390\/cells10020351"},{"issue":"11","key":"3017_CR97","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1093\/carcin\/bgu181","volume":"35","author":"D Cheishvili","year":"2014","unstructured":"Cheishvili D, et al. Synergistic effects of combined DNA methyltransferase inhibition and MBD2 depletion on breast cancer cells; MBD2 depletion blocks 5-aza-2\u2019-deoxycytidine-triggered invasiveness. Carcinogenesis. 2014;35(11):2436\u201346.","journal-title":"Carcinogenesis"},{"key":"3017_CR98","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s40170-019-0196-9","volume":"7","author":"M Rosso","year":"2019","unstructured":"Rosso M, et al. Characterization of the molecular changes associated with the overexpression of a novel epithelial cadherin splice variant mRNA in a breast cancer model using proteomics and bioinformatics approaches: identification of changes in cell metabolism and an increased expression of lactate dehydrogenase B. Cancer Metab. 2019;7:5.","journal-title":"Cancer Metab"},{"issue":"169","key":"3017_CR99","doi-asserted-by":"publisher","first-page":"169ra12","DOI":"10.1126\/scitranslmed.3004688","volume":"5","author":"R Hatami","year":"2013","unstructured":"Hatami R, et al. KLF6-SV1 drives breast cancer metastasis and is associated with poor survival. Sci Transl Med. 2013;5(169):169ra12.","journal-title":"Sci Transl Med"},{"issue":"8","key":"3017_CR100","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.7150\/thno.83920","volume":"13","author":"M Liu","year":"2023","unstructured":"Liu M, et al. The interplay between non-coding RNAs and alternative splicing: from regulatory mechanism to therapeutic implications in cancer. Theranostics. 2023;13(8):2616\u201331.","journal-title":"Theranostics"},{"issue":"1","key":"3017_CR101","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/s41467-020-14304-1","volume":"11","author":"X Hu","year":"2020","unstructured":"Hu X, et al. The RNA-binding protein AKAP8 suppresses tumor metastasis by antagonizing EMT-associated alternative splicing. Nat Commun. 2020;11(1):486.","journal-title":"Nat Commun"},{"issue":"7","key":"3017_CR102","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1038\/s41580-019-0126-2","volume":"20","author":"T Kurosaki","year":"2019","unstructured":"Kurosaki T, Popp MW, Maquat LE. Quality and quantity control of gene expression by nonsense-mediated mRNA decay. Nat Rev Mol Cell Biol. 2019;20(7):406\u201320.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3017_CR103","doi-asserted-by":"crossref","unstructured":"Deng L, et al. MYC-driven U2SURP regulates alternative splicing of SAT1 to promote triple-negative breast cancer progression. Cancer Lett. 2023;560:216124.","DOI":"10.1016\/j.canlet.2023.216124"},{"issue":"5","key":"3017_CR104","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1158\/0008-5472.CAN-08-1997","volume":"69","author":"M Hirschfeld","year":"2009","unstructured":"Hirschfeld M, et al. Alternative splicing of Cyr61 is regulated by hypoxia and significantly changed in breast cancer. Cancer Res. 2009;69(5):2082\u201390.","journal-title":"Cancer Res"},{"issue":"5","key":"3017_CR105","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1007\/s00280-019-03945-9","volume":"84","author":"YN Sun","year":"2019","unstructured":"Sun YN, et al. Downregulation of SRSF3 by antisense oligonucleotides sensitizes oral squamous cell carcinoma and breast cancer cells to paclitaxel treatment. Cancer Chemother Pharmacol. 2019;84(5):1133\u201343.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"14","key":"3017_CR106","doi-asserted-by":"publisher","first-page":"eadj4009","DOI":"10.1126\/sciadv.adj4009","volume":"10","author":"L Deng","year":"2024","unstructured":"Deng L, et al. SF3A2 promotes progression and cisplatin resistance in triple-negative breast cancer via alternative splicing of MKRN1. Sci Adv. 2024;10(14):eadj4009.","journal-title":"Sci Adv"},{"issue":"11","key":"3017_CR107","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1038\/bjc.2013.247","volume":"108","author":"TO Nielsen","year":"2013","unstructured":"Nielsen TO, et al. Directing HER4 mRNA expression towards the CYT2 isoform by antisense oligonucleotide decreases growth of breast cancer cells in vitro and in vivo. Br J Cancer. 2013;108(11):2291\u20138.","journal-title":"Br J Cancer"},{"issue":"1","key":"3017_CR108","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12860-017-0134-z","volume":"18","author":"J Huun","year":"2017","unstructured":"Huun J, et al. Impact of the MDM2 splice-variants MDM2-A, MDM2-B and MDM2-C on cytotoxic stress response in breast cancer cells. BMC Cell Biol. 2017;18(1):17.","journal-title":"BMC Cell Biol"},{"issue":"12","key":"3017_CR109","doi-asserted-by":"publisher","first-page":"3190","DOI":"10.1158\/0008-5472.CAN-17-3514","volume":"78","author":"YZ Zheng","year":"2018","unstructured":"Zheng YZ, et al. PHF5A Epigenetically Inhibits Apoptosis to Promote Breast Cancer Progression. Cancer Res. 2018;78(12):3190\u2013206.","journal-title":"Cancer Res"},{"issue":"2","key":"3017_CR110","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1515\/cclm-2018-0272","volume":"57","author":"A Kladi-Skandali","year":"2018","unstructured":"Kladi-Skandali A, Sideris DC, Scorilas A. BCL2L12: a multiply spliced gene with independent prognostic significance in breast cancer. Clin Chem Lab Med (CCLM). 2018;57(2):276\u201387.","journal-title":"Clin Chem Lab Med (CCLM)"},{"issue":"2","key":"3017_CR111","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1038\/nsmb.2207","volume":"19","author":"O Anczukow","year":"2012","unstructured":"Anczukow O, et al. The splicing factor SRSF1 regulates apoptosis and proliferation to promote mammary epithelial cell transformation. Nat Struct Mol Biol. 2012;19(2):220\u20138.","journal-title":"Nat Struct Mol Biol"},{"key":"3017_CR112","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/1471-2407-14-176","volume":"14","author":"S Khan","year":"2014","unstructured":"Khan S, et al. Early diagnostic value of survivin and its alternative splice variants in breast cancer. BMC Cancer. 2014;14:176.","journal-title":"BMC Cancer"},{"issue":"1","key":"3017_CR113","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s12964-019-0450-3","volume":"17","author":"N Hinz","year":"2019","unstructured":"Hinz N, Jucker M. Distinct functions of AKT isoforms in breast cancer: a comprehensive review. Cell Commun Signal. 2019;17(1):154.","journal-title":"Cell Commun Signal"},{"key":"3017_CR114","doi-asserted-by":"publisher","first-page":"103382","DOI":"10.1016\/j.redox.2024.103382","volume":"77","author":"N Wang","year":"2024","unstructured":"Wang N, et al. FMRP protects breast cancer cells from ferroptosis by promoting SLC7A11 alternative splicing through interacting with hnRNPM. Redox Biol. 2024;77:103382.","journal-title":"Redox Biol"},{"key":"3017_CR115","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.phrs.2019.03.008","volume":"143","author":"E Buoso","year":"2019","unstructured":"Buoso E, et al. Cortisol-induced SRSF3 expression promotes GR splicing, RACK1 expression and breast cancer cells migration. Pharmacol Res. 2019;143:17\u201326.","journal-title":"Pharmacol Res"},{"key":"3017_CR116","doi-asserted-by":"crossref","unstructured":"Kansara S, et al. LncRNA-mediated orchestrations of alternative splicing in the landscape of breast cancer. Biochim Biophys Acta Gene Regul Mech. 2024;1867(2):195017.","DOI":"10.1016\/j.bbagrm.2024.195017"},{"issue":"7","key":"3017_CR117","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1158\/1535-7163.MCT-17-0026","volume":"16","author":"T Liu","year":"2017","unstructured":"Liu T, et al. TRA2A Promoted Paclitaxel Resistance and Tumor Progression in Triple-Negative Breast Cancers via Regulating Alternative Splicing. Mol Cancer Ther. 2017;16(7):1377\u201388.","journal-title":"Mol Cancer Ther"},{"key":"3017_CR118","doi-asserted-by":"crossref","unstructured":"Wang C, et al. SRPK1 acetylation modulates alternative splicing to regulate cisplatin resistance in breast cancer cells. Commun Biology. 2020;3(1):268.","DOI":"10.1038\/s42003-020-0983-4"},{"issue":"5","key":"3017_CR119","doi-asserted-by":"publisher","first-page":"2676","DOI":"10.1093\/nar\/gkz1213","volume":"48","author":"M Dutertre","year":"2020","unstructured":"Dutertre M, et al. ZRANB2 and SYF2-mediated splicing programs converging on ECT2 are involved in breast cancer cell resistance to doxorubicin. Nucleic Acids Res. 2020;48(5):2676\u201393.","journal-title":"Nucleic Acids Res"},{"issue":"7","key":"3017_CR120","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1111\/jcmm.17716","volume":"27","author":"J Wang","year":"2023","unstructured":"Wang J, et al. Influence of cyclin D1 splicing variants expression on breast cancer chemoresistance via CDK4\/CyclinD1-pRB\u2010E2F1 pathway. J Cell Mol Med. 2023;27(7):991\u20131005.","journal-title":"J Cell Mol Med"},{"issue":"9","key":"3017_CR121","doi-asserted-by":"publisher","first-page":"2778","DOI":"10.1158\/0008-5472.CAN-16-0186","volume":"76","author":"Y Wang","year":"2016","unstructured":"Wang Y, et al. The BRCA1-Delta11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin. Cancer Res. 2016;76(9):2778\u201390.","journal-title":"Cancer Res"},{"key":"3017_CR122","doi-asserted-by":"crossref","unstructured":"Hao Y, et al. Mitochondria-localized MBD2c facilitates mtDNA transcription and drug resistance. Nat Chem Biol. 2025;21(6):926\u201338.","DOI":"10.1038\/s41589-024-01776-1"},{"key":"3017_CR123","doi-asserted-by":"publisher","first-page":"19","DOI":"10.4137\/GEG.S35500","volume":"7","author":"K Inoue","year":"2015","unstructured":"Inoue K, Fry EA. Aberrant Splicing of Estrogen Receptor, HER2, and CD44 Genes in Breast Cancer. Genet Epigenet. 2015;7:19\u201332.","journal-title":"Genet Epigenet"},{"key":"3017_CR124","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jsbmb.2018.04.007","volume":"182","author":"K Ohe","year":"2018","unstructured":"Ohe K, et al. HMGA1a induces alternative splicing of estrogen receptor alpha in MCF-7 human breast cancer cells. J Steroid Biochem Mol Biol. 2018;182:21\u20136.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"3017_CR125","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3389\/fonc.2016.00145","volume":"6","author":"R Bellerby","year":"2016","unstructured":"Bellerby R, et al. Overexpression of Specific CD44 Isoforms Is Associated with Aggressive Cell Features in Acquired Endocrine Resistance. Front Oncol. 2016;6:145.","journal-title":"Front Oncol"},{"issue":"39","key":"3017_CR126","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.1038\/s41388-024-03134-w","volume":"43","author":"S Yu","year":"2024","unstructured":"Yu S, et al. Alternative splicing of ALDOA confers tamoxifen resistance in breast cancer. Oncogene. 2024;43(39):2901\u201313.","journal-title":"Oncogene"},{"key":"3017_CR127","doi-asserted-by":"crossref","unstructured":"Pandkar MR, et al. Oncometabolite lactate enhances breast cancer progression by orchestrating histone lactylation-dependent c-Myc expression. Translational Oncol. 2023;37:101758.","DOI":"10.1016\/j.tranon.2023.101758"},{"issue":"22","key":"3017_CR128","doi-asserted-by":"publisher","first-page":"6248","DOI":"10.7150\/thno.28721","volume":"8","author":"R Gao","year":"2018","unstructured":"Gao R, et al. CD44ICD promotes breast cancer stemness via PFKFB4-mediated glucose metabolism. Theranostics. 2018;8(22):6248\u201362.","journal-title":"Theranostics"},{"key":"3017_CR129","doi-asserted-by":"crossref","unstructured":"Zanini G, et al. Differential Expression of Lonp1 Isoforms in Cancer Cells. Cells. 2022;11(23):3940.","DOI":"10.3390\/cells11233940"},{"key":"3017_CR130","doi-asserted-by":"crossref","unstructured":"Li J, Huang G. Insulin receptor alternative splicing in breast and prostate cancer. Cancer Cell Int. 2024;24(1):62.","DOI":"10.1186\/s12935-024-03252-1"},{"issue":"46","key":"3017_CR131","doi-asserted-by":"publisher","first-page":"e2207201119","DOI":"10.1073\/pnas.2207201119","volume":"119","author":"YS Yang","year":"2022","unstructured":"Yang YS, et al. Superenhancer drives a tumor-specific splicing variant of MARCO to promote triple-negative breast cancer progression. Proc Natl Acad Sci U S A. 2022;119(46):e2207201119.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"3017_CR132","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/s41419-021-03436-x","volume":"12","author":"T Pani","year":"2021","unstructured":"Pani T, et al. Alternative splicing of ceramide synthase 2 alters levels of specific ceramides and modulates cancer cell proliferation and migration in Luminal B breast cancer subtype. Cell Death Dis. 2021;12(2):171.","journal-title":"Cell Death Dis"},{"key":"3017_CR133","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1038\/srep01689","volume":"3","author":"J Eswaran","year":"2013","unstructured":"Eswaran J, et al. RNA sequencing of cancer reveals novel splicing alterations. Sci Rep. 2013;3:1689.","journal-title":"Sci Rep"},{"issue":"1","key":"3017_CR134","doi-asserted-by":"publisher","first-page":"14158","DOI":"10.1038\/s41598-024-65035-y","volume":"14","author":"Y Deguchi","year":"2024","unstructured":"Deguchi Y, Kikutake C, Suyama M. Subtype-specific alternative splicing events in breast cancer identified by large-scale data analysis. Sci Rep. 2024;14(1):14158.","journal-title":"Sci Rep"},{"key":"3017_CR135","doi-asserted-by":"crossref","unstructured":"Zhang F et al. Identification of novel alternative splicing biomarkers for breast cancer with LC\/MS\/MS and RNA-Seq. BMC Bioinformatics. 2020;21(Suppl 9):541.","DOI":"10.1186\/s12859-020-03824-8"},{"issue":"2","key":"3017_CR136","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s13402-015-0265-1","volume":"39","author":"A Aljada","year":"2016","unstructured":"Aljada A, et al. Altered Lamin A\/C splice variant expression as a possible diagnostic marker in breast cancer. Cell Oncol (Dordr). 2016;39(2):161\u201374.","journal-title":"Cell Oncol (Dordr)"},{"key":"3017_CR137","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/1741-7015-8-44","volume":"8","author":"JP Dales","year":"2010","unstructured":"Dales JP, et al. Hypoxia inducible factor 1alpha gene (HIF-1alpha) splice variants: potential prognostic biomarkers in breast cancer. BMC Med. 2010;8:44.","journal-title":"BMC Med"},{"issue":"2","key":"3017_CR138","doi-asserted-by":"publisher","first-page":"188502","DOI":"10.1016\/j.bbcan.2021.188502","volume":"1875","author":"B Goyal","year":"2021","unstructured":"Goyal B, et al. Diagnostic, prognostic, and therapeutic significance of long non-coding RNA MALAT1 in cancer. Biochim Biophys Acta Rev Cancer. 2021;1875(2):188502.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"12","key":"3017_CR139","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1158\/1535-7163.MCT-17-0461","volume":"16","author":"S Chan","year":"2017","unstructured":"Chan S, et al. Basal-A Triple-Negative Breast Cancer Cells Selectively Rely on RNA Splicing for Survival. Mol Cancer Ther. 2017;16(12):2849\u201361.","journal-title":"Mol Cancer Ther"},{"issue":"22","key":"3017_CR140","doi-asserted-by":"publisher","first-page":"6296","DOI":"10.1158\/1078-0432.CCR-13-0485","volume":"19","author":"FA Eskens","year":"2013","unstructured":"Eskens FA, et al. Phase I pharmacokinetic and pharmacodynamic study of the first-in-class spliceosome inhibitor E7107 in patients with advanced solid tumors. Clin Cancer Res. 2013;19(22):6296\u2013304.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"3017_CR141","doi-asserted-by":"publisher","first-page":"4491","DOI":"10.1038\/s41467-021-24741-1","volume":"12","author":"C Cretu","year":"2021","unstructured":"Cretu C, et al. Structural basis of intron selection by U2 snRNP in the presence of covalent inhibitors. Nat Commun. 2021;12(1):4491.","journal-title":"Nat Commun"},{"key":"3017_CR142","doi-asserted-by":"crossref","unstructured":"Sudhakaran M, et al. Transcriptome reprogramming through alternative splicing triggered by apigenin drives cell death in triple-negative breast cancer. Cell Death Dis. 2023;14(12):824.","DOI":"10.1038\/s41419-023-06342-6"},{"key":"3017_CR143","doi-asserted-by":"crossref","unstructured":"Sun X, et al. Bioengineered Ferritin Nanocarriers for Cancer Therapy. Int J Mol Sci. 2021;22(13):7023.","DOI":"10.3390\/ijms22137023"},{"issue":"25","key":"3017_CR144","doi-asserted-by":"publisher","first-page":"21473","DOI":"10.1021\/acsomega.2c00997","volume":"7","author":"H Abuzaid","year":"2022","unstructured":"Abuzaid H, et al. Apoferritin-Encapsulated Jerantinine A for Transferrin Receptor Targeting and Enhanced Selectivity in Breast Cancer Therapy. ACS Omega. 2022;7(25):21473\u201382.","journal-title":"ACS Omega"},{"issue":"12","key":"3017_CR145","doi-asserted-by":"publisher","first-page":"e0293700","DOI":"10.1371\/journal.pone.0293700","volume":"18","author":"F Fontana","year":"2023","unstructured":"Fontana F, et al. Transferrin receptor in primary and metastatic breast cancer: Evaluation of expression and experimental modulation to improve molecular targeting. PLoS ONE. 2023;18(12):e0293700.","journal-title":"PLoS ONE"},{"key":"3017_CR146","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/978-3-031-66686-5_6","volume":"1465","author":"MF Guefack","year":"2024","unstructured":"Guefack MF, Bhatnagar S. Advances in Epigenetic Therapeutics for Breast Cancer. Adv Exp Med Biol. 2024;1465:89\u201397.","journal-title":"Adv Exp Med Biol"},{"key":"3017_CR147","doi-asserted-by":"crossref","unstructured":"Shuai Y, et al. The N6-methyladenosine writer METTL3 promotes breast cancer progression through YTHDF2-dependent posttranscriptional silencing of GSDMD. Apoptosis. 2025;30(1\u20132):226\u201338.","DOI":"10.1007\/s10495-024-02037-1"},{"issue":"11","key":"3017_CR148","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.1016\/j.chembiol.2024.08.003","volume":"31","author":"K Zhang","year":"2024","unstructured":"Zhang K, et al. A chemical screen identifies PRMT5 as a therapeutic vulnerability for paclitaxel-resistant triple-negative breast cancer. Cell Chem Biol. 2024;31(11):1942\u201357. e6.","journal-title":"Cell Chem Biol"},{"key":"3017_CR149","doi-asserted-by":"crossref","unstructured":"Lin J-C. Therapeutic Applications of Targeted Alternative Splicing to Cancer Treatment. Int J Mol Sci. 2017;19(1):75.","DOI":"10.3390\/ijms19010075"},{"issue":"1","key":"3017_CR150","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s13046-021-02001-w","volume":"40","author":"Z Dou","year":"2021","unstructured":"Dou Z, et al. Aberrant Bcl-x splicing in cancer: from molecular mechanism to therapeutic modulation. J Exp Clin Cancer Res. 2021;40(1):194.","journal-title":"J Exp Clin Cancer Res"},{"issue":"43","key":"3017_CR151","doi-asserted-by":"publisher","first-page":"17779","DOI":"10.1073\/pnas.1108482108","volume":"108","author":"F Zammarchi","year":"2011","unstructured":"Zammarchi F, et al. Antitumorigenic potential of STAT3 alternative splicing modulation. Proc Natl Acad Sci. 2011;108(43):17779\u201384.","journal-title":"Proc Natl Acad Sci"},{"issue":"7","key":"3017_CR152","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1002\/ijc.30574","volume":"140","author":"LD Smith","year":"2017","unstructured":"Smith LD, et al. Novel splice-switching oligonucleotide promotes BRCA1 aberrant splicing and susceptibility to PARP inhibitor action. Int J Cancer. 2017;140(7):1564\u201370.","journal-title":"Int J Cancer"},{"key":"3017_CR153","doi-asserted-by":"crossref","unstructured":"Yang W, et al. Targeting SNRNP200-induced splicing dysregulation offers an immunotherapy opportunity for glycolytic triple-negative breast cancer. Cell Discovery. 2024;10(1):96.","DOI":"10.1038\/s41421-024-00715-7"},{"issue":"1","key":"3017_CR154","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1038\/s41467-025-56913-8","volume":"16","author":"NK Leclair","year":"2025","unstructured":"Leclair NK, et al. Antisense oligonucleotide-mediated TRA2beta poison exon inclusion induces the expression of a lncRNA with anti-tumor effects. Nat Commun. 2025;16(1):1670.","journal-title":"Nat Commun"},{"issue":"11","key":"3017_CR155","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1038\/s41401-023-01116-4","volume":"44","author":"B Zhang","year":"2023","unstructured":"Zhang B, et al. Truncated SCRIB isoform promotes breast cancer metastasis through HNRNP A1 mediated exon 16 skipping. Acta Pharmacol Sin. 2023;44(11):2307\u201321.","journal-title":"Acta Pharmacol Sin"},{"issue":"6","key":"3017_CR156","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/s44320-024-00034-9","volume":"20","author":"AD Fronk","year":"2024","unstructured":"Fronk AD, et al. Development and validation of AI\/ML derived splice-switching oligonucleotides. Mol Syst Biol. 2024;20(6):676\u2013701.","journal-title":"Mol Syst Biol"},{"key":"3017_CR157","doi-asserted-by":"publisher","first-page":"1214489","DOI":"10.3389\/fmolb.2023.1214489","volume":"10","author":"PK Tiwari","year":"2023","unstructured":"Tiwari PK, et al. CRISPR\/Cas9 as a therapeutic tool for triple negative breast cancer: from bench to clinics. Front Mol Biosci. 2023;10:1214489.","journal-title":"Front Mol Biosci"},{"issue":"3","key":"3017_CR158","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","volume":"21","author":"M Bekes","year":"2022","unstructured":"Bekes M, Langley DR, Crews CM. PROTAC targeted protein degraders: the past is prologue. Nat Rev Drug Discov. 2022;21(3):181\u2013200.","journal-title":"Nat Rev Drug Discov"},{"issue":"11","key":"3017_CR159","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1016\/j.chembiol.2021.04.018","volume":"28","author":"RA Gama-Brambila","year":"2021","unstructured":"Gama-Brambila RA, et al. A PROTAC targets splicing factor 3B1. Cell Chem Biol. 2021;28(11):1616\u2013e16278.","journal-title":"Cell Chem Biol"},{"issue":"6","key":"3017_CR160","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1002\/anie.202012330","volume":"60","author":"A Ghidini","year":"2021","unstructured":"Ghidini A, et al. RNA-PROTACs: Degraders of RNA-Binding Proteins. Angew Chem Int Ed Engl. 2021;60(6):3163\u20139.","journal-title":"Angew Chem Int Ed Engl"},{"key":"3017_CR161","doi-asserted-by":"publisher","first-page":"106793","DOI":"10.1016\/j.ejps.2024.106793","volume":"198","author":"Z Wang","year":"2024","unstructured":"Wang Z, Che S, Yu Z. PROTAC: Novel degradable approach for different targets to treat breast cancer. Eur J Pharm Sci. 2024;198:106793.","journal-title":"Eur J Pharm Sci"},{"key":"3017_CR162","doi-asserted-by":"publisher","first-page":"12177","DOI":"10.2147\/IJN.S552644","volume":"20","author":"X Mu","year":"2025","unstructured":"Mu X, et al. Nanotechnology Advances Proteolysis Targeting Chimeras (PROTACs): Transition From Basic Research to Clinical Application. Int J Nanomed. 2025;20:12177\u201398.","journal-title":"Int J Nanomed"},{"key":"3017_CR163","doi-asserted-by":"publisher","first-page":"123621","DOI":"10.1016\/j.biomaterials.2025.123621","volume":"325","author":"Y Liu","year":"2026","unstructured":"Liu Y, et al. Proteolysis-targeting chimera (PROTAC) nanomedicines toward cancer treatment: From synthesis to therapeutic delivery. Biomaterials. 2026;325:123621.","journal-title":"Biomaterials"},{"issue":"3","key":"3017_CR164","doi-asserted-by":"publisher","first-page":"eabg6711","DOI":"10.1126\/sciadv.abg6711","volume":"8","author":"DFT Veiga","year":"2022","unstructured":"Veiga DFT, et al. A comprehensive long-read isoform analysis platform and sequencing resource for breast cancer. Sci Adv. 2022;8(3):eabg6711.","journal-title":"Sci Adv"},{"key":"3017_CR165","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.semcancer.2019.10.023","volume":"72","author":"M Benvenuto","year":"2021","unstructured":"Benvenuto M, et al. Tumor antigens heterogeneity and immune response-targeting neoantigens in breast cancer. Semin Cancer Biol. 2021;72:65\u201375.","journal-title":"Semin Cancer Biol"}],"container-title":["Cell Communication and Signaling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12964-026-03017-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-026-03017-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-026-03017-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:03:25Z","timestamp":1788221005000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12964-026-03017-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,19]]},"references-count":165,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3017"],"URL":"https:\/\/doi.org\/10.1186\/s12964-026-03017-5","relation":{},"ISSN":["1478-811X"],"issn-type":[{"value":"1478-811X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,19]]},"assertion":[{"value":"19 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"464"}}